The diminished ability of insulin to promote glucose disposal and storage in muscle has been ascribed to impaired activation of glycogen synthase (GS). It is possible that decreased glucose storage could occur as a consequence of decreased glucose uptake, and that GS is impaired secondarily. Muscle glucose uptake in 15 diabetic subjects was matched to 15 nondiabetic subjects by maintaining fasting hyperglycemia during infusion of insulin. Leg muscle glucose uptake, glucose oxidation (local indirect calorimetry), release of glycolytic products, and muscle glucose storage, as well as muscle GS and pyruvate dehydrogenase (PDH) were determined before and during insulin infusion. Basal leg glucose oxidation and PDH were increased in the diabetics. Insulin-stimulated leg glucose uptake in the diabetics (8.05±1.41 Mmol/Imin-100 ml leg tissue]) did not differ from controls (5.64±0.37). Insulin-stimulated leg glucose oxidation, nonoxidized glycolysis, and glucose storage (2.48±0.27, 0.68±0.15, and 5.04±1.34 gmol/Imin -100 ml], respectively) were not different from controls (2.18±0.12, 0.62±0.16, and 2.83±031). PDH and GS in noninsulin-dependent diabetes mellitus (NIDDM) were also normal during insulin infusion. When diabetics were restudied after being rendered euglycemic by overnight insulin infusion, GS and PDH were reduced compared with hyperglycemia. Thus, fasting hyperglycemia is sufficient to normalize insulin-stimulated muscle glucose uptake in NIDDM, and glucose is distributed normally to glycogenesis and glucose oxidation, possibly by normalization of GS and PDH. (J. Clin. Invest.
rendered euglycemic by means of an insulin infusion, the deficit in insulin-stimulated systemic glucose disposal can largely be accounted for by decreased glucose storage in muscle (5) . Because impaired insulin activation of muscle glycogen synthase is correlated with impaired glucose storage, it has been suggested that an intra-cellular defect is responsible for decreased glucose disposal (5). However, it is possible that decreased glucose storage could occur solely as a consequence of decreased glucose uptake, and that impaired activation of glycogen synthase is a secondary effect.
Distinguishing between these possibilities is critical to understanding the biochemical mechanism(s) responsible for skeletal muscle insulin resistance. One way of distinguishing between the two would be to match rates of muscle glucose uptake in NIDDM and nondiabetic subjects at equivalent hyperinsulinemia and assess oxidative and nonoxidative muscle glucose metabolism. Revers et al. (6) found that maintaining fasting hyperglycemia in NIDDM subjects during infusion of insulin was sufficient to match rates of systemic glucose disposal to those obtained in euglycemic nondiabetics. This experimental approach would be useful to probe the regulation of intracellular muscle glucose metabolism. Thorburn et al. (7) adjusted hyperglycemia in NIDDM subjects to obtain equivalent systemic glucose disposal to euglycemic controls (at matched insulin infusions), and found reduced systemic glucose oxidation and increased plasma lactate concentrations. These investigators inferred that there was a higher rate of muscle Cori cycle activity in NIDDM. However, under those experimental conditions these abnormalities cannot be attributed solely to skeletal muscle, because the extreme hyperglycemia induced in that study (-20 mmol/liter) would increase lactate production by other tissues such as liver (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . In another study, Shulman et al. (18), using nuclear magnetic resonance techniques, found that during hyperglycemia in NIDDM the effects of insulin resistance in muscle are accounted for, nearly entirely, by impaired glycogen formation. However, the activity of muscle glycogen synthase, muscle glucose uptake, and lactate release were not determined in that study, leaving the biochemical mechanism of insulin resistance unknown.
These studies were undertaken to resolve the controversy of which metabolic pathways within skeletal muscle are affected by insulin resistance in NIDDM and, more specifically, to determine whether or not defects in intracellular glucose metabolism occur independently ofglucose uptake. In order to more directly address these questions in skeletal muscle, limb balance rather than systemic techniques were used to estimate muscle glucose uptake and metabolism.
The limb balance technique is a direct in vivo method for assessment ofglucose metabolism across a large bed of muscle, and has been used to specifically measure glucose uptake (8, 11, 19) , nonoxidized glycolysis (release of lactate) (20), and glucose oxidation (21, 22 ) (net indirect calorimetry based on gas exchange across the limb). The subtraction ofthe latter two pathways from glucose uptake provides an estimate of muscle glucose storage (22) . The limb balance method provides direct data on muscle metabolism which cannot be obtained with studies of systemic glucose metabolism. Additionally, enzyme activities in biopsies of this muscle bed can be directly related to flux through the various pathways of glucose metabolism.
Our findings demonstrate that, in NIDDM, the fasting level of hyperglycemia is sufficient to normalize muscle glucose uptake during an insulin infusion. These normal rates of insulin-stimulated glucose uptake allow glucose storage, oxidation, and nonoxidized glycolysis to proceed at normal rates, which suggests that the site of muscle insulin resistance in NIDDM may be proximal to all these pathways. However, at hyperglycemia, insulin-stimulated muscle glycogen synthase (GS) and pyruvate dehydrogenase (PDH) activities were normalized in NIDDM, indicating that regulation of intracellular pathways of glucose metabolism may also be partially responsible for normalization of muscle glucose storage and oxidation. Finally, the finding of increased basal muscle glucose oxidation and PDH activity provides evidence that defects in basal muscle metabolism may contribute to systemic basal metabolic abnormalities in NIDDM.
Methods
Subjects (Table I ). The studies were approved by the Institutional Review Board of the University of Pittsburgh School of Medicine and The Eye and Ear Institute of Pittsburgh, and informed written consent was obtained from each subject. The clinical characteristics of each subject are shown in Table I . All of the nondiabetic volunteers had normal glucose tolerance, as determined with a I g/kg (maximum 75 g) 2 h oral glucose tolerance test (23). 14 ofthe 15 subjects with NIDDM were being treated with oral hypoglycemic agents that were discontinued at least 2 wk before the study. One ofthe diabetics had been treated by diet alone, and none ofthese subjects had been treated with insulin. Subjects were instructed to consume a diet containing at least 200 g of carbohydrate per day for the 3 d preceding admission and to not exercise on the day before the study. Body fat percentages were determined using bio-impedance (24).
Study design. Subjects were admitted to the University of Pittsburgh General Clinical Research Center on the evening before the study. They were fed a 10 kcal/kg evening meal (50% carbohydrate, 35% protein, and 15% fat) at 6 p.m., and fasted overnight. In the morning, catheters were placed in an antecubital vein for infusion of glucose and insulin, and a radial artery and a femoral vein for blood sampling. After an additional 90 min, simultaneous arterial and The basal and clamp arterial and venous blood CO2 and 02 contents were estimated as the mean of six respective determinations in each period. The coefficient of variation was calculated for each individual, and the mean intrasubject coefficient ofvariation was 1% for arterial C02, femoral venous CO2, and arterial 02, and 4% for femoral venous 02 content.
Leg 02 consumption (VO2) and CO2 production (VCO2) were calculated as the product of the arteriovenous difference and leg blood flow. Rates of leg carbohydrate and lipid oxidation were calculated using the equations of Frayn (26) , employing a constant for limb protein oxidation of 85 nmol/(min -100 ml tissue), as kindly suggested by E. Ferrannini (personal communication), based on previous studies of muscle protein oxidation (27) .
Analysis. Whole blood glucose was measured with a glucose analyzer (Yellow Springs Instrument Co., Yellow Springs, OH). Lactate and alanine determinations were made using microfluorometric assays (28, 29) performed on extracts ofwhole blood samples which had been immediately deproteinized with an equal volume of chilled 7% perchloric acid at the bedside. The supernatant was separated and stored at -70°C. Arterial plasma insulin was assayed by the method of Herbert et al. (30) . Plasma FFA was measured enzymatically on arterial plasma samples using a commercial kit (NEFA C; Wako Pure Chemical Industries, Ltd., Osaka, Japan).
PDH and GS activities. Assays ofskeletal muscle PDH activity and GS activity were performed as previously described (31). PDH was assayed in the presence of fluoride with 50MuM magnesium to measure active (PDAa), and in the absence of fluoride with 10 mM magnesium to measure total PDH activity (PDHJ). The pyruvate concentration in both cases was 1 mmol/liter. The fractional velocity of PDH (PDHFV) is defined as PDHS/PDHt. GS was assayed in the presence of 0.1 or 10 mmol/liter glucose 6-phosphate (G6P) and 0.3 mmol/liter UDPG.
GSFv is defined as the activity of GS assayed at 0.1 mmol/liter G6P divided by the activity of the enzyme assayed at 10 mmol/liter G6P.
Calculations. Glucose, lactate, alanine, 02, and CO2 balance across the leg were calculated as the product ofthe arterio-venous concentration difference and blood flow and are expressed in units of Mimol/(min -100 ml leg tissue). Leg glucose clearance was calculated by dividing leg glucose uptake by arterial glucose concentration.
Net leg glucose storage was calculated as the difference between glucose uptake and the sum of glucose oxidation and release of glycolytic products. This estimate of net storage can be positive or negative. If positive, it was interpreted as net glycogen synthesis, while if negative, as net glycogenolysis. When combined as a measure of release of glycolytic products, net leg lactate and alanine release was expressed in terms of glucose equivalents.
Statistics. Data are expressed as mean±SEM. Statistical comparisons were made using paired or unpaired t tests, where appropriate, using a 0.05 significance level. All correlation analyses were performed by parametric methods (Pearson's r). Statistical analyses were performed using RS/ I (BBN Software, Cambridge, MA).
Results
Clinical characteristics (Table I ). The diabetic and nondiabetic subjects were matched for age, body mass index (BMI), and percentage body fat, although the diabetics had a higher waist to hip ration. All subjects were male. The groups were moderately obese, as indicated by the mean BMIs, which is characteristic of the population of patients with NIDDM. Fasting plasma glucose ranged from 7.1 to 14.9 mmol/liter in the NIDDM subjects. Each control subject had normal glucose tolerance as determined with a 75 g oral glucose tolerance test; the mean plasma glucose values were 5.15±0.12 at 0 min, 9.37±0.39 at 60 min and 6.56±0.36 mmol/liter at 120 min.
Glucose clamp. In the postabsorptive state, blood glucose was 11.01±0.59 mmol/liter in NIDDM subjects and was kept constant during insulin infusion (10.96±0.54 mmol/liter) by exogenous glucose infusion. In controls, blood glucose was 4.88±0.10 basally and 4.94±0.10 mmol/liter during insulin infusion. The coefficient of variation of arterial blood glucose concentration was < 4% throughout the insulin infusion. Basal plasma insulin tended to be higher in NIDDM (12.8±1.5 mU/liter) than in the controls (9.6±0.8), but this was not significant (P = 0.07). Insulin concentrations were equivalent during the last 30 min of insulin infusion (78±3 vs. 77±3 mU/liter, NS) in NIDDM and control subjects. Basal leg blood flow was lower in the NIDDM subjects (5.34±0.18 ml/[min. 100 ml tissue]) than in the controls (6.04±0.28, P < 0.05), and did not change significantly in either group during the insulin infusion. The rate of glucose infusion required to maintain euglycemia in the nondiabetics during insulin infusion was 234±16 mg/(m2_ min), which was not significantly different from that required to maintain hyperglycemia in the subjects with NIDDM (330±48 mg/[m2_ min]).
Leg glucose uptake (Table II) . Basal leg glucose uptake was similar in controls and NIDDM (0.57±0.06 vs. 0.73±0.16 ,umol/[min. 100 ml tissue], respectively). During infusion of insulin, the time course of stimulation of leg glucose uptake was similar in both groups and steady-state conditions were attained by 180 min. During the final 30 min of insulin infusion, leg glucose uptake was 5.64±0.37 Mmol/(min' 100 ml tissue) in controls and 8.06±1.41 Mmol/(min * 100 ml tissue) in NIDDM. Due to significantly greater variability among subjects with NIDDM (F-test on ratio of variances, P < 0.01), the difference in leg glucose uptake between NIDDM and controls was not significant (P = 0.06). Leg glucose clearance was reduced in NIDDM during the final 30 min of insulin infusion (0.74±0.13 vs. 1.14±0.07 ml/[min. 100 ml tissue], P < 0.01).
Neither basal nor insulin-stimulated leg glucose uptake was correlated with fasting blood glucose in the diabetic subjects. Rates of exogenous glucose infusion were correlated with rates of leg glucose uptake during insulin infusion in NIDDM (r = 0.83, P = 0.001) and in controls (r = 0.68, P = 0.005). Leg nonoxidized glycolysis (lactate and alanine balance, Tables II and III) . Basally, arterial blood lactate was significantly higher in NIDDM subjects than euglycemic controls (Table I1I) Arterial blood alanine concentrations (Table III) were equivalent in controls and diabetics and did not change during insulin infusion in controls (0.27±0.02 vs. 0.27±0.02 mmol/ liter), whereas in NIDDM arterial alanine increased modestly (0.25±0.02 vs. 0.29±0.02 mmol/liter, P < 0.05). Basally, there was a net release of alanine by leg tissue, which was similar in controls and in NIDDM. Infusion of insulin decreased net alanine release by leg in controls (0.43±0.09 to 0.30±0.09 Mumol/(min. 100 ml tissue], P < 0.05) and in NIDDM (0.51±0.08 to 0.35±0.06 umol/[min. 100 ml tissue], P < 0.05).
In controls and diabetics, infusion ofinsulin produced similar increases in net release of lactate and decreases in net release of alanine by the leg (Table III) . The increment in arterial blood lactate between basal and steady-state levels during the insulin infusion was correlated with the increment in arterial alanine (r = 0.86, P < 0.01), as was the increment in arterial lactate and the rate of exogenous glucose infusion (r = 0.64, P < 0.05). However, there was no correlation between the changes in net release oflactate by leg tissues during insulin infusion and increments in arterial lactate (r = 0.025, NS).
The sum of leg net lactate and alanine release can be considered to be an estimate of the rate of nonoxidized glycolysis (22) . For this purpose, lactate and alanine release were expressed in terms ofglucose equivalents (1 mol glucose = 2 mol lactate or alanine). As seen in Table II 
16.14±0.99 Mmol/[min-100 ml tissue])
. Because of the increased CO2 production during insulin infusion, the RQ across the leg tissue increased significantly in controls (from 0.84±0.02 to 0.97±0.02, P < 0.01), but the increment in RQ in NIDDM (0.92±0.03 vs. 0.96±0.02) was not significant (see Fig. 1 ).
Rates of gas exchange across the leg were used to calculate rates ofglucose and lipid oxidation by the leg (Table II, Fig. 2 Fig. 3 ; r = 0.79, P < 0.01), but there was no such correlation in the diabetics. Leg glucose storage (Table II) . Rates of leg glucose uptake, leg nonoxidized glycolysis, and leg glucose oxidation were used to calculate net leg glucose storage. In diabetics and controls during postabsorptive conditions, leg glucose oxidation was more than double the rate of leg glucose uptake, and net release of lactate plus alanine was equivalent to leg glucose uptake. As Fig. 4) . Under basal conditions, glycogen synthase activity at 0.1 and 10 mmol/liter G6P in diabetics did not differ from control values. In both groups, infusion of insulin resulted in significant stimulation ofGS activity assayed at 0.1 mmol/liter G6P, and this stimulation did not differ from that observed in controls (2.82±0.43 vs. 3.05±0.39 nmol/[min * mg], controls vs. NIDDM). Insulin infusion did not increase GS activity assayed with 10 mmol/ liter. As a result, infusion of insulin-stimulated GSFv (Table   IV) 
NIDDM, NS).
The relationships between insulin activation of GSFv and insulin stimulation of leg glucose uptake and storage in subjects with NIDDM are shown in Fig. 4 , a and b, respectively.
Insulin stimulation of GSFv was correlated with insulin stimulation of leg glucose uptake (r = 0.651, P < 0.01) and leg glucose storage (r = 0.592, P < 0.02). There were no significant correlations in the control subjects between insulin stimulation of glycogen synthase and leg glucose uptake (r = 0.05) or leg glucose storage (r = -0.133).
Basally, PDHa (Table VI) Fig. 10 ), as were PDHa and basal leg glucose oxidation (r = 0.393, P < 0.05).
Glycogen synthase and PDH activity in NIDDM subjects during euglycemia (Table VII) . In four subjects with NIDDM, GS and PDH were assayed in biopsies taken under euglycemic conditions after slow overnight insulin infusion (4-12 mU/[m2. min]) and then after four hours ofinfusion ofinsulin at a rate of 40 mU/(m2 _ min) while euglycemia was maintained. After overnight insulin, the plasma insulin concentration was 17+4 mU/ml in these subjects; during the 40 mU/(m2* min) insulin infusion, plasma insulin reached a steady-state plateau of 67±4 mU/ml, which was not different from those insulin concentrations achieved during insulin infusion at hyperglycemia. Basal GS activity and GSFv were significantly decreased by 75% during euglycemia as compared with hyperglycemia (Table VII) . Muscle GS activity and GSFv were similarly decreased at euglycemia during insulin infusion. In like fashion, overnight euglycemia resulted in a 50-60% decrease in muscle PDH. basally and during insulin infusion. Unlike the case for GS, though, total PDH activity (PDH,) was also decreased during euglycemia to a comparable extent as was PDHa. Therefore, PDHFv during euglycemia was not different to that during hyperglycemia (Table VII) .
Discussion
Critical to understanding the mechanism responsible for skeletal muscle insulin resistance in NIDDM is the question of whether impaired muscle glucose storage and oxidation occur independently of defects in glucose uptake. To address this issue, we used the limb balance technique to compare skeletal muscle glucose oxidation and storage, as well as muscle GS and PDH activities under conditions in which rates of muscle glucose uptake were matched in NIDDM and nondiabetic subjects at equivalent plasma insulin concentrations.
As an initial attempt to achieve comparable rates of muscle glucose uptake in NIDDM and nondiabetic subjects, we studied the NIDDM subjects at their prevailing fasting plasma glucose levels. This was done because Revers et al. had reported that fasting hyperglycemia was able to fully compensate for insulin resistance in NIDDM (6) . This approach was successful since, in the present study, we found that basal and insulin-stimulated rates of leg glucose uptake were equivalent in NIDDM subjects studied at their fasting plasma glucose levels and nondiabetic volunteers studied at euglycemia. These results suggest that fasting hyperglycemia in a patient with NIDDM is the equilibrium point at which glucose production by the liver normalizes the rate of muscle glucose uptake. Although rates of systemic and leg glucose uptake were equivalent, glucose clearance systemically and across the leg was reduced in the NIDDM subjects. Thus, hyperglycemia in NIDDM subjects did not completely eliminate insulin resistance. In both groups of subjects, leg glucose uptake was strongly correlated with systemic glucose disposal, accounting for nearly three-quarters of the variability in insulin-stimulated glucose disposal. Therefore, muscle is a key tissue in which compensation for insulin resistance by hyperglycemia takes place, and the prevailing fasting hyperglycemia of an individual with NIDDM is sufficient for this phenomenon to occur.
Despite normal basal leg glucose uptake, there were significant abnormalities in basal muscle glucose and lipid metabolism in the subjects with NIDDM. The basal rate of leg glucose oxidation was significantly greater in the diabetics, and this was associated with significantly increased muscle PDH activity. This increase in basal leg glucose oxidation in NIDDM occurred in spite of significantly greater plasma FFA concentrations, which suggests that there may be an abnormality in FFA clearance by muscle in NIDDM. Decreased systemic clearance of FFA in subjects with NIDDM has been reported (32) . Although the extent to which muscle contributes to this defect is unknown, it may be significant, since muscle in normal subjects predominantly uses FFA as its oxidative substrate. Parenthetically, decreased use of FFA by muscle could lead to increased plasma FFA levels and increased hepatic lipid oxidation, which could in turn lead to increased hepatic glucose production (33) and be a mechanism that links defects in skeletal muscle with those in liver in NIDDM. Such an increase in hepatic lipid oxidation could offset the decrease in muscle lipid oxidation, resulting in unchanged or even increased systemic lipid oxidation in NIDDM. Finally, even though muscle glucose oxidation was increased, which suggests increased glycolysis, under basal conditions in NIDDM release of glycolytic products from the leg was normal. This is consistent with the observed increase in PDHFv in that group.
In spite of this, arterial lactate levels were greater than in controls, implying that increased blood lactate in NIDDM does not come from muscle. Having successfully attained equivalent rates of insulinstimulated muscle glucose uptake in NIDDM and nondiabetic subjects, it was possible to assess whether normalization of glucose uptake compensated for intracellular pathways of glucose metabolism which are decreased when glucose uptake is reduced. If this were the case, it would provide evidence that impaired muscle glucose oxidation and storage in NIDDM are secondary to reduced muscle glucose uptake.
In contrast to the abnormalities found in leg glucose metabolism in NIDDM subjects studied under basal conditions, leg glucose, storage, oxidation, and release of glycolytic products proceeded at normal rates in NIDDM subjects studied when their fasting hyperglycemia was maintained during an insulin infusion. It could be concluded from this that the defect in insulin-stimulated glucose metabolism in muscle occurs at a point that is proximal to all the pathways studied. A likely candidate for the step responsible for this defect is glucose transport. The simplest explanation for the phenomena observed in the present study is that, in NIDDM, hyperglycemia normalizes insulin-stimulated glucose uptake by mass action. Normalization of flux ofglucose into the cell would then result in normal rates of intracellular glucose metabolism. A similar explanation for muscle insulin resistance in patients with insulin dependent diabetes has recently been put forth (34).
However, these findings do not exclude the possibility that hyperglycemia in NIDDM normalizes leg glucose metabolism by means of direct or indirect effects on muscle GS and PDH. This study provides some evidence that is consistent with this idea. We found that hyperglycemia normalized muscle GS and PDH activities in NIDDM subjects who had a profound defect in the activity of this enzyme when they were studied after being rendered euglycemic by an overnight insulin infusion. One interpretation of these data is that hyperglycemia increased glucose transport by mass action, resulting in increased intracellular concentrations of effectors of GS phosphatase (35, such as G6P) or PDH phosphatase (such as pyruvate), which could result in increased activities of GS and PDH through covalent modification. The normalized GS and PDH activities could then have participated at least in part in normalization of insulin-stimulated muscle glucose storage and oxidation. This effect may be limited to NIDDM, since hyperglycemia only minimally stimulates muscle glycogen synthase in nondiabetic controls (36) .
These findings in subjects with NIDDM who were studied while hyperglycemic, differ significantly from those recently reported by Thorburn et al. (7), who reported decreased insulin-stimulated systemic glucose oxidation and muscle glycogen synthase activity, but paradoxically increased systemic glucose storage and elevated plasma lactate concentrations. They concluded from this that, despite normal rates of systemic glucose disposal, muscle glucose metabolism was not normalized, and attributed the increased plasma lactate concentration in NIDDM to increased muscle lactate release. These findings indicate that matching leg glucose uptake to control values by maintaining fasting hyperglycemia normalizes muscle glucose oxidation and storage in NIDDM, and that increased blood lactate concentrations in the diabetics do not come from muscle. The differences between these results and those of Thorburn et al. (7) most likely result from differences in study design and subject selection. In that study, in order to normalize glucose disposal, plasma glucose had to be increased to a mean of 20 mmol/liter, with some subjects being studied at a plasma glucose concentration as high as 30 mmol/liter. The increase in hyperglycemia necessary to match glucose disposal rates to controls was probably due to the fact that the nondiabetic control subjects in the Thorburn study appear to be extremely insulin sensitive compared with those in this study and those used by Revers et al. The reasons for the disparity in insulin sensitivity between the control subjects of Thorburn et al. and those in this study are not readily apparent. Nevertheless, at such high glucose concentrations in the NIDDM subjects, significant uptake and metabolism of glucose (including glycogen deposition and glycolysis) must have occurred in the liver and splanchnic bed (9) (10) (11) (12) (13) (14) (15) (16) (17) . These tissues are likely to be the sources of the increased plasma lactate concentrations as well as much of the increase in systemic nonoxidative glucose metabolism they observed in the diabetics. Under such conditions, it is not surprising that muscle glycogen synthase activity did not reflect systemic nonoxidative glucose metabolism. Therefore, under conditions of hyperinsulinemia and hyperglycemia, inferences made about muscle from knowledge of systemic glucose metabolism must be made judiciously. These findings should not be interpreted to mean that in daily life hyperglycemia is somehow beneficial for the patient with NIDDM. The conclusions apply only to conditions of steady-state plasma insulin concentrations matched to controls. After a meal, the pattern of plasma insulin levels in the diabetic will be different than the nondiabetic, so there may not be complete normalization of the pathways of skeletal muscle glucose metabolism, to the extent this depends on insulin concentration. Nevertheless, this study provides data that is useful in determining the biochemical site of insulin resistance.
In conclusion, our results show that basal muscle glucose oxidation is increased in NIDDM in spite of increased plasma FFA levels, suggesting that there is a defect in utilization of FFA by muscle in NIDDM. Further studies will be required to determine whether such a defect in FFA clearance exists as well as what effects it might have on systemic metabolism. Our results also indicate that, during insulin stimulation, maintenance of prevailing hyperglycemia in NIDDM subjects is sufficient to normalize muscle glucose uptake, the oxidative and nonoxidative pathways of muscle glucose metabolism, and muscle glycogen synthase and PDH activities. These findings are consistent with a mechanism whereby fasting hyperglycemia increases until uptake ofglucose by muscle is normalized. Once inside muscle cells, glucose is then distributed normally to glycogen formation and glucose oxidation, possibly via normalization of glycogen synthase and PDH activities by hyperglycemia.
